Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02446847 · ClinicalTrials.gov registry record · Phase 2
3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption
A Phase 2 study, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT02446847: Completed Phase 2 study, sponsored by Rockefeller University.
NCT02446847 is a Phase 2 study that has completed, run by Rockefeller University. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02446847, a Phase 2 study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study evaluates the effects of two infusions of 3BNC117 in preventing or delaying rebound of viral load during a brief treatment interruption of standard ART and its safety during a brief analytical interruption of antiretroviral therapy.
Primary Outcome
Virologic rebound is defined as confirmed plasma HIV-1 RNA level \> 200 copies/ml in two separate occasions
Interventions
- DRUG 3BNC117
- OTHER ART Interruption
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-03-11 |
| Est. Completion | 2017-03-25 |
| Phase | Phase 2 |
What the finished NCT02446847 record still lists
NCT02446847 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which 3BNC117 is the first listed.
NCT02446847 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02446847 about?
NCT02446847 is a clinical study titled "3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption". This study evaluates the effects of two infusions of 3BNC117 in preventing or delaying rebound of viral load during a brief treatment interruption of standard ART and its safety during a brief analytical interruption of antiretroviral therapy.
What is the current status of trial NCT02446847?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2015-03-11. Estimated completion is 2017-03-25.
What interventions are being tested in trial NCT02446847?
The interventions under investigation include: 3BNC117 (DRUG), ART Interruption (OTHER).
Who is sponsoring clinical trial NCT02446847?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02446847's enrollment target sits among peer trials
16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI